Anticardiolipin antibodies in patients with systemic lupus erythematosus.

Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients. Ann Rheum Dis (1988) 1.44

Isotype distribution of anticardiolipin antibodies in systemic lupus erythematosus: prospective analysis of a series of 100 patients. Ann Rheum Dis (1990) 1.14

Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment. Ann Rheum Dis (2005) 1.14

Antiphospholipid syndrome: five year follow up. Ann Rheum Dis (1991) 1.11

Renal artery thrombosis and hypertension in a 13 year old girl with antiphospholipid syndrome. Ann Rheum Dis (1990) 1.03

Clinical importance of persistence of anticardiolipin antibodies in systemic lupus erythematosus. Ann Rheum Dis (1990) 1.02

Fluctuations of anticardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective study. Ann Rheum Dis (1989) 0.95

Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome? Ann Rheum Dis (1994) 0.95

Haematological manifestations of lupus. Lupus Sci Med (2015) 0.89

Ethnic and geographical variation in antiphospholipid (Hughes) syndrome. Ann Rheum Dis (2005) 0.84

Autoimmune hemolytic anemia in systemic lupus erythematosus: association with thrombocytopenia. Clin Rheumatol (2010) 0.84

Cardiac valvular disease in patients with systemic lupus erythematosus. Relationship with anticardiolipin antibodies. Clin Rheumatol (2003) 0.83

Value of anticardiolipin antibodies for monitoring disease activity in systemic lupus erythematosus and other rheumatic diseases. Clin Rheumatol (1997) 0.81

Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheum Dis (1992) 0.79

Calorie restriction prevents the occlusive coronary vascular disease of autoimmune (NZW x BXSB)F1 mice. Proc Natl Acad Sci U S A (1994) 0.78

Cutaneous manifestations associated with antiphospholipid antibodies in patients with suspected primary antiphospholipid syndrome: a case-control study. Ann Rheum Dis (1993) 0.78

Clinical manifestations and antiphosphatidylserine antibodies in patients with systemic lupus erythematosus: is there an association? Clin Rheumatol (2006) 0.77

Binding affinity of serum immunoglobulin G to cardiolipin and other phospholipids in patients with systemic lupus erythematosus and syphilis. Infect Immun (1988) 0.76

Reassessing the status of antiphospholipid syndrome in systemic lupus erythematosus. Ann Rheum Dis (1992) 0.76

Recurrent cerebral infarction and the antiphospholipid syndrome: effect of intravenous gammaglobulin in a patient with systemic lupus erythematosus. Ann Rheum Dis (1990) 0.75

The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum (1996) 6.88

Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol (1999) 3.66

Mortality in systemic lupus erythematosus. Arthritis Rheum (2006) 3.61

EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis (2007) 3.32

Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus (2000) 2.81

The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum (1997) 2.49

Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet (1986) 2.38

Reduction of the diagnostic window with a new combined p24 antigen and human immunodeficiency virus antibody screening assay. J Virol Methods (1998) 2.31

Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature (1991) 2.28

The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol (2000) 2.26

Anti-actin specificity of human smooth muscle antibodies in chronic active hepatitis. Clin Exp Immunol (1976) 2.24

Evolution and clonal traits of Mycobacterium tuberculosis complex in Guinea-Bissau. J Clin Microbiol (1999) 2.23

Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum (2007) 2.18

Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int (2007) 2.08

Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study Group. AIDS (2000) 2.08

An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum (2005) 1.96

Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken) (2010) 1.84

F-Actin-depolymerizing activity of human serum. Eur J Biochem (1979) 1.71

Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval. Br J Rheumatol (1990) 1.70

Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand (1985) 1.65

Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis Rheum (2008) 1.65

Does primary fibromyalgia exist? Br J Rheumatol (1990) 1.64

Further immunological studies of sera containing anti-mitochondrial antibodies, type M 5. Clin Exp Immunol (1984) 1.63

Evidence for circulating immune complexes in sarcoidosis. Clin Exp Immunol (1974) 1.59

Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) (1989) 1.54

Biochemical heterogeneity of Mycobacterium tuberculosis complex isolates in Guinea-Bissau. J Clin Microbiol (1993) 1.47

Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis. Am J Med (1990) 1.47

Systemic lupus erythematosus in an adult population in southern Sweden: incidence, prevalence and validity of ARA revised classification criteria. Br J Rheumatol (1985) 1.38

Complement components, complement activation, and acute phase response in systemic lupus erythematosus. Int Arch Allergy Appl Immunol (1984) 1.36

Tuberculosis mortality during a civil war in Guinea-Bissau. JAMA (2001) 1.36

Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope. AIDS Res Hum Retroviruses (1996) 1.36

Multilocus markers for mouse genome analysis: PCR amplification based on single primers of arbitrary nucleotide sequence. Mamm Genome (1992) 1.36

Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. J Rheumatol (1994) 1.35

Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol (1992) 1.34

Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum (2008) 1.34

Circulating anti-elastase in systemic lupus erythematosus. Lancet (1989) 1.33

Complement deficiency and disease: an update. Mol Immunol (2006) 1.33

A susceptibility locus for human systemic lupus erythematosus (hSLE1) on chromosome 2q. J Autoimmun (2000) 1.29

Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm. AIDS (1998) 1.27

Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis (2009) 1.27

Autonomic nerve function in rheumatoid arthritis of varying severity. Scand J Rheumatol (1983) 1.25

Palmoplantar pustulosis and sternocostoclavicular arthro-osteitis. Ann Rheum Dis (1988) 1.25

Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol (2000) 1.23

Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine-induced lupus. Clin Exp Immunol (1990) 1.20

Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis (2005) 1.19

Risk factors for developing systemic lupus erythematosus: a case-control study in southern Sweden. Rheumatology (Oxford) (2002) 1.16

Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses (1997) 1.16

Vaccine protection against HIV-2 infection in cynomolgus monkeys. AIDS Res Hum Retroviruses (1991) 1.16

Experimental infection of cynomolgus monkeys (Macaca fascicularis) with HIV-2. J Acquir Immune Defic Syndr (1989) 1.16

Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis (2006) 1.15

Arthritis in pigs induced by dietary factors. Microbiologic, clinical and histologic studies. Clin Exp Immunol (1971) 1.15

Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. J Infect Dis (1996) 1.13

Circulating immune complexes in Mycoplasma pneumoniae infection. J Immunol (1974) 1.13

An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis (2010) 1.12

Nerve palsy after knee arthroplasty in patients with rheumatoid arthritis. Scand J Rheumatol (1983) 1.12

Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission. J Virol (1997) 1.11

Shortening of the diagnostic window with a new combined HIV p24 antigen and anti-HIV-1/2/O screening test. J Virol Methods (2000) 1.10

Letter: Antibodies against thyroid cells in Yersinia enterocolitica infection. Lancet (1974) 1.10

The immunoglobulin content of normal serum. Acta Med Scand (1967) 1.09

Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity. Proc Natl Acad Sci U S A (1991) 1.08

Polyarteritis nodosa when applying the Chapel Hill nomenclature--a descriptive study on ten patients. Rheumatology (Oxford) (2006) 1.08

MhcDRB-sequences from cynomolgus macaques (Macaca fascicularis) of different origin. Tissue Antigens (2004) 1.07

Further characterization of the Ca2+-dependent F-actin-depolymerizing protein of human serum. Eur J Biochem (1982) 1.07

Anti-actin antibodies. Curr Top Microbiol Immunol (1978) 1.07

Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden. Pediatr Infect Dis J (1988) 1.07

Complement classical pathway components are all important in clearance of apoptotic and secondary necrotic cells. Clin Exp Immunol (2009) 1.07

Complement activating rheumatoid factors in rheumatoid arthritis studied by haemolysis in gel: relation to antibody class and response to treatment with podophyllotoxin derivatives. Clin Exp Rheumatol (1985) 1.07

Clinical and serological features of severe vasculitis in rheumatoid arthritis: prognostic implications. Ann Rheum Dis (1987) 1.07

Association between SLE nephritis and polymorphic variants of the CRP and FcgammaRIIIa genes. Rheumatology (Oxford) (2007) 1.06

Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken) (2012) 1.06

Increased monocyte transcription of the proteinase 3 gene in small vessel vasculitis. Clin Exp Immunol (2005) 1.06

Outcome of incomplete systemic lupus erythematosus after 10 years. Lupus (2004) 1.06

Anticardiolipin antibodies and complement in ninety-nine women with habitual abortion. Am J Obstet Gynecol (1987) 1.06

Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) (2007) 1.05

Predictors of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol (2000) 1.04

Drug susceptibility in Mycobacterium tuberculosis of a sample of patients in Guinea Bissau. Tuber Lung Dis (1993) 1.03

False positive ELISA tests for anticardiolipin antibodies in sera from patients with repeated abortion, rheumatologic disorders and primary biliary cirrhosis: correlation with elevated polyclonal IgM and implications for patients with repeated abortion. Clin Exp Immunol (1988) 1.03